Peter Gottlieb
Concepts (550)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 133 | 2023 | 3471 | 6.670 |
Why?
| Insulin | 49 | 2023 | 2219 | 2.650 |
Why?
| Islets of Langerhans | 22 | 2023 | 745 | 1.810 |
Why?
| Insulin-Secreting Cells | 18 | 2021 | 334 | 1.750 |
Why?
| Hypoglycemic Agents | 20 | 2023 | 1081 | 1.590 |
Why?
| C-Peptide | 26 | 2023 | 142 | 1.420 |
Why?
| Autoantibodies | 33 | 2022 | 1382 | 1.330 |
Why?
| B-Lymphocytes | 9 | 2023 | 781 | 1.120 |
Why?
| Antilymphocyte Serum | 8 | 2021 | 66 | 1.050 |
Why?
| Autoantigens | 15 | 2021 | 406 | 1.020 |
Why?
| Monitoring, Ambulatory | 4 | 2010 | 86 | 1.000 |
Why?
| Autoimmunity | 19 | 2023 | 835 | 0.970 |
Why?
| Antibodies, Monoclonal, Humanized | 12 | 2023 | 666 | 0.950 |
Why?
| T-Lymphocytes | 23 | 2023 | 1793 | 0.940 |
Why?
| CD4-Positive T-Lymphocytes | 13 | 2023 | 997 | 0.910 |
Why?
| Blood Glucose | 15 | 2021 | 2008 | 0.880 |
Why?
| Immunosuppressive Agents | 9 | 2023 | 693 | 0.870 |
Why?
| Proinsulin | 6 | 2016 | 49 | 0.790 |
Why?
| Clinical Trials as Topic | 11 | 2020 | 1006 | 0.790 |
Why?
| Blood Glucose Self-Monitoring | 4 | 2010 | 551 | 0.770 |
Why?
| CD4 Antigens | 2 | 2013 | 127 | 0.680 |
Why?
| Immunologic Factors | 7 | 2019 | 228 | 0.670 |
Why?
| Addison Disease | 7 | 2012 | 41 | 0.650 |
Why?
| Diabetes Mellitus, Type 2 | 6 | 2020 | 2236 | 0.650 |
Why?
| Preventive Medicine | 2 | 2018 | 41 | 0.640 |
Why?
| Adult | 84 | 2023 | 33168 | 0.640 |
Why?
| Polyendocrinopathies, Autoimmune | 3 | 2010 | 18 | 0.640 |
Why?
| Humans | 149 | 2023 | 125132 | 0.640 |
Why?
| Prediabetic State | 7 | 2018 | 241 | 0.630 |
Why?
| Adolescent | 67 | 2022 | 19411 | 0.620 |
Why?
| CD8-Positive T-Lymphocytes | 10 | 2019 | 717 | 0.610 |
Why?
| Insulin Antibodies | 6 | 2022 | 104 | 0.570 |
Why?
| Granulocyte Colony-Stimulating Factor | 6 | 2021 | 71 | 0.560 |
Why?
| Young Adult | 44 | 2022 | 11385 | 0.550 |
Why?
| Child | 60 | 2023 | 20014 | 0.550 |
Why?
| Peptide Fragments | 12 | 2016 | 713 | 0.540 |
Why?
| HLA-DQ Antigens | 10 | 2019 | 179 | 0.540 |
Why?
| Mycophenolic Acid | 3 | 2012 | 81 | 0.530 |
Why?
| Autoimmune Diseases | 10 | 2017 | 406 | 0.520 |
Why?
| Immunoglobulin G | 6 | 2018 | 808 | 0.490 |
Why?
| Steroid 21-Hydroxylase | 5 | 2012 | 30 | 0.490 |
Why?
| Monocytes | 4 | 2016 | 523 | 0.480 |
Why?
| Glutamate Decarboxylase | 9 | 2022 | 166 | 0.470 |
Why?
| Mice, Inbred NOD | 16 | 2023 | 582 | 0.470 |
Why?
| Peptides | 4 | 2021 | 884 | 0.470 |
Why?
| Cytokines | 9 | 2018 | 1927 | 0.460 |
Why?
| Biomarkers | 12 | 2021 | 3736 | 0.460 |
Why?
| Vaccines, DNA | 1 | 2013 | 33 | 0.450 |
Why?
| Cystic Fibrosis | 3 | 2012 | 990 | 0.450 |
Why?
| Female | 83 | 2022 | 64890 | 0.440 |
Why?
| Chromogranin A | 1 | 2013 | 40 | 0.440 |
Why?
| Male | 76 | 2022 | 60793 | 0.430 |
Why?
| Myeloid Cells | 1 | 2014 | 128 | 0.420 |
Why?
| Immunologic Memory | 7 | 2019 | 322 | 0.420 |
Why?
| Immunomodulation | 1 | 2013 | 89 | 0.420 |
Why?
| Interferon-gamma | 6 | 2021 | 749 | 0.420 |
Why?
| T-Lymphocyte Subsets | 8 | 2018 | 406 | 0.420 |
Why?
| alpha 1-Antitrypsin | 1 | 2014 | 125 | 0.420 |
Why?
| Disease Progression | 16 | 2021 | 2577 | 0.400 |
Why?
| Immunotherapy | 4 | 2013 | 499 | 0.400 |
Why?
| Hypoglycemia | 6 | 2009 | 413 | 0.390 |
Why?
| Dendritic Cells | 2 | 2014 | 445 | 0.380 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 304 | 0.380 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2021 | 58 | 0.360 |
Why?
| Diabetes Mellitus | 2 | 2023 | 988 | 0.350 |
Why?
| Immunoconjugates | 4 | 2014 | 90 | 0.350 |
Why?
| CD3 Complex | 5 | 2019 | 94 | 0.340 |
Why?
| HLA-DR3 Antigen | 5 | 2022 | 79 | 0.330 |
Why?
| HLA-DR Antigens | 7 | 2018 | 225 | 0.310 |
Why?
| Antibodies, Monoclonal | 5 | 2010 | 1300 | 0.310 |
Why?
| Clonal Anergy | 3 | 2018 | 54 | 0.310 |
Why?
| Histocompatibility Antigens Class I | 5 | 2011 | 176 | 0.290 |
Why?
| Cation Transport Proteins | 3 | 2017 | 125 | 0.290 |
Why?
| Toll-Like Receptors | 3 | 2014 | 170 | 0.290 |
Why?
| Double-Blind Method | 12 | 2021 | 1725 | 0.280 |
Why?
| Age of Onset | 6 | 2020 | 484 | 0.280 |
Why?
| Area Under Curve | 8 | 2021 | 305 | 0.270 |
Why?
| Zinc Transporter 8 | 4 | 2021 | 87 | 0.270 |
Why?
| Receptors, Interleukin-2 | 2 | 2006 | 67 | 0.260 |
Why?
| Time Factors | 10 | 2020 | 6780 | 0.260 |
Why?
| Middle Aged | 35 | 2021 | 29112 | 0.250 |
Why?
| Animals | 29 | 2023 | 34345 | 0.240 |
Why?
| Software | 2 | 2008 | 647 | 0.240 |
Why?
| Antigen Presentation | 3 | 2018 | 194 | 0.240 |
Why?
| Insulin, Regular, Human | 2 | 2023 | 33 | 0.240 |
Why?
| Insulin, Isophane | 1 | 2004 | 17 | 0.240 |
Why?
| T-Lymphocytes, Regulatory | 6 | 2023 | 364 | 0.230 |
Why?
| Precision Medicine | 3 | 2023 | 378 | 0.230 |
Why?
| Pregnancy in Diabetics | 2 | 2003 | 88 | 0.230 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 3 | 2013 | 84 | 0.220 |
Why?
| Protein Precursors | 2 | 2016 | 125 | 0.220 |
Why?
| Immunotherapy, Active | 2 | 2014 | 9 | 0.220 |
Why?
| Mice | 23 | 2023 | 15984 | 0.210 |
Why?
| Polyethylene Glycols | 3 | 2018 | 577 | 0.210 |
Why?
| Plasmids | 3 | 2013 | 361 | 0.210 |
Why?
| Histocompatibility Testing | 4 | 2013 | 125 | 0.210 |
Why?
| Islets of Langerhans Transplantation | 2 | 2015 | 68 | 0.200 |
Why?
| Epitopes, T-Lymphocyte | 4 | 2011 | 171 | 0.200 |
Why?
| Immune Tolerance | 2 | 2017 | 338 | 0.200 |
Why?
| Interleukin-1beta | 3 | 2014 | 382 | 0.200 |
Why?
| Lymphocyte Depletion | 2 | 2013 | 123 | 0.200 |
Why?
| Receptors, Antigen, T-Cell | 5 | 2022 | 638 | 0.200 |
Why?
| Methyldopa | 2 | 2019 | 8 | 0.200 |
Why?
| Recombinant Fusion Proteins | 2 | 2015 | 658 | 0.190 |
Why?
| Imatinib Mesylate | 1 | 2021 | 63 | 0.190 |
Why?
| Treatment Outcome | 11 | 2020 | 9790 | 0.190 |
Why?
| Necrobiosis Lipoidica | 1 | 2001 | 2 | 0.190 |
Why?
| Haplotypes | 5 | 2022 | 496 | 0.190 |
Why?
| Asymptomatic Diseases | 1 | 2021 | 84 | 0.180 |
Why?
| Histocompatibility Antigens Class II | 3 | 2011 | 356 | 0.180 |
Why?
| History, 21st Century | 2 | 2018 | 181 | 0.180 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 22 | 0.180 |
Why?
| Platelet-Derived Growth Factor | 1 | 2001 | 86 | 0.180 |
Why?
| Dose-Response Relationship, Drug | 5 | 2019 | 2026 | 0.180 |
Why?
| Genetic Predisposition to Disease | 8 | 2018 | 2382 | 0.180 |
Why?
| History, 20th Century | 2 | 2018 | 290 | 0.180 |
Why?
| Child, Preschool | 17 | 2022 | 9938 | 0.170 |
Why?
| Gastrointestinal Microbiome | 2 | 2018 | 557 | 0.170 |
Why?
| Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 11 | 0.170 |
Why?
| Biomarkers, Pharmacological | 1 | 2020 | 28 | 0.170 |
Why?
| Biological Variation, Population | 1 | 2019 | 24 | 0.170 |
Why?
| Cytomegalovirus | 2 | 2018 | 153 | 0.170 |
Why?
| Hepatitis Delta Virus | 3 | 1994 | 6 | 0.170 |
Why?
| Graves Disease | 2 | 2017 | 32 | 0.170 |
Why?
| Luminescence | 2 | 2016 | 35 | 0.170 |
Why?
| Th2 Cells | 2 | 2014 | 167 | 0.170 |
Why?
| Forkhead Transcription Factors | 3 | 2016 | 186 | 0.160 |
Why?
| Cytoprotection | 1 | 2018 | 58 | 0.160 |
Why?
| Biomedical Research | 2 | 2018 | 641 | 0.150 |
Why?
| Immunity, Cellular | 2 | 2018 | 277 | 0.150 |
Why?
| Thyroiditis, Autoimmune | 1 | 2017 | 15 | 0.150 |
Why?
| Abatacept | 5 | 2023 | 43 | 0.150 |
Why?
| HLA-A2 Antigen | 1 | 2017 | 39 | 0.150 |
Why?
| Diabetes Mellitus, Experimental | 2 | 1990 | 216 | 0.150 |
Why?
| Inflammation | 4 | 2018 | 2612 | 0.150 |
Why?
| Twins, Dizygotic | 1 | 2018 | 184 | 0.150 |
Why?
| HLA-DR4 Antigen | 4 | 2022 | 76 | 0.150 |
Why?
| Lymphocyte Activation | 6 | 2017 | 1077 | 0.140 |
Why?
| Thyroid Gland | 1 | 2017 | 85 | 0.140 |
Why?
| Twins, Monozygotic | 1 | 2018 | 216 | 0.140 |
Why?
| Antibody-Producing Cells | 1 | 2017 | 29 | 0.140 |
Why?
| Treatment Failure | 1 | 2018 | 348 | 0.140 |
Why?
| Cell Separation | 2 | 2017 | 299 | 0.140 |
Why?
| Magnetic Fields | 1 | 2017 | 23 | 0.140 |
Why?
| Regeneration | 1 | 1998 | 177 | 0.140 |
Why?
| Th1 Cells | 2 | 2009 | 137 | 0.140 |
Why?
| Dysbiosis | 1 | 2018 | 151 | 0.140 |
Why?
| Antibody Formation | 1 | 2018 | 282 | 0.140 |
Why?
| Influenza, Human | 1 | 2022 | 569 | 0.140 |
Why?
| Glucose Tolerance Test | 4 | 2021 | 373 | 0.140 |
Why?
| Cytomegalovirus Infections | 1 | 2018 | 194 | 0.140 |
Why?
| Follow-Up Studies | 8 | 2021 | 4824 | 0.140 |
Why?
| Trans-Activators | 1 | 1998 | 383 | 0.130 |
Why?
| RNA, Catalytic | 2 | 1994 | 183 | 0.130 |
Why?
| Administration, Oral | 1 | 2018 | 785 | 0.130 |
Why?
| Nanoparticles | 2 | 2017 | 328 | 0.130 |
Why?
| Host-Pathogen Interactions | 1 | 2018 | 312 | 0.130 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 832 | 0.130 |
Why?
| Tuftsin | 3 | 1983 | 4 | 0.120 |
Why?
| Homeodomain Proteins | 1 | 1998 | 476 | 0.120 |
Why?
| Drug Therapy, Combination | 3 | 2018 | 1006 | 0.120 |
Why?
| Dermatologic Agents | 1 | 2015 | 65 | 0.120 |
Why?
| Epitopes | 4 | 2017 | 450 | 0.120 |
Why?
| Family | 2 | 2017 | 640 | 0.120 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 311 | 0.120 |
Why?
| Phenotype | 2 | 2019 | 3153 | 0.110 |
Why?
| Graft Rejection | 2 | 2015 | 555 | 0.110 |
Why?
| Law Enforcement | 1 | 2014 | 41 | 0.110 |
Why?
| Risk Factors | 12 | 2018 | 9549 | 0.110 |
Why?
| Criminals | 1 | 2014 | 27 | 0.110 |
Why?
| Crime | 1 | 2014 | 60 | 0.110 |
Why?
| Withholding Treatment | 1 | 2013 | 70 | 0.110 |
Why?
| Pancreatectomy | 1 | 2015 | 171 | 0.110 |
Why?
| Primary Cell Culture | 1 | 2013 | 155 | 0.110 |
Why?
| Transglutaminases | 1 | 2013 | 145 | 0.110 |
Why?
| Cytotoxicity, Immunologic | 2 | 2013 | 205 | 0.110 |
Why?
| Adjuvants, Immunologic | 1 | 2014 | 211 | 0.100 |
Why?
| Reproducibility of Results | 3 | 2009 | 3047 | 0.100 |
Why?
| Gene Expression | 2 | 2013 | 1528 | 0.100 |
Why?
| Communicable Diseases | 1 | 2014 | 140 | 0.100 |
Why?
| Nucleic Acid Conformation | 3 | 1994 | 680 | 0.100 |
Why?
| Adaptive Immunity | 1 | 2013 | 163 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2009 | 1885 | 0.100 |
Why?
| Receptors, Immunologic | 2 | 1983 | 213 | 0.100 |
Why?
| Flow Cytometry | 4 | 2019 | 1108 | 0.100 |
Why?
| DNA, Viral | 1 | 1994 | 360 | 0.100 |
Why?
| Alleles | 5 | 2011 | 865 | 0.100 |
Why?
| Diabetic Angiopathies | 2 | 2010 | 276 | 0.100 |
Why?
| Proportional Hazards Models | 3 | 2021 | 1191 | 0.100 |
Why?
| Epstein-Barr Virus Infections | 1 | 2012 | 73 | 0.100 |
Why?
| Cross-Sectional Studies | 6 | 2023 | 4854 | 0.100 |
Why?
| Thyroiditis | 1 | 1991 | 3 | 0.100 |
Why?
| Down-Regulation | 1 | 2014 | 652 | 0.090 |
Why?
| Lymphocyte Count | 3 | 2019 | 140 | 0.090 |
Why?
| Polymorphism, Genetic | 3 | 2010 | 669 | 0.090 |
Why?
| HLA-B Antigens | 1 | 2011 | 56 | 0.090 |
Why?
| Herpesviridae Infections | 1 | 2012 | 147 | 0.090 |
Why?
| Recombinant Proteins | 3 | 2018 | 1327 | 0.090 |
Why?
| Interleukin-6 | 2 | 2012 | 710 | 0.090 |
Why?
| Cells, Cultured | 7 | 2017 | 4159 | 0.090 |
Why?
| Pilot Projects | 3 | 2021 | 1530 | 0.090 |
Why?
| Organophosphorus Compounds | 1 | 2011 | 79 | 0.090 |
Why?
| Glycine | 1 | 2011 | 177 | 0.090 |
Why?
| Endocrine Cells | 1 | 2010 | 6 | 0.090 |
Why?
| Cryopreservation | 1 | 2011 | 104 | 0.090 |
Why?
| Drug Delivery Systems | 1 | 2013 | 309 | 0.090 |
Why?
| Transplantation Immunology | 1 | 1990 | 32 | 0.090 |
Why?
| Insulin, Long-Acting | 3 | 2004 | 52 | 0.090 |
Why?
| HLA Antigens | 4 | 2022 | 235 | 0.090 |
Why?
| Insulin Glargine | 3 | 2004 | 75 | 0.090 |
Why?
| Mental Health Services | 1 | 2014 | 345 | 0.080 |
Why?
| Inflammation Mediators | 2 | 2010 | 515 | 0.080 |
Why?
| Muromonab-CD3 | 1 | 2009 | 23 | 0.080 |
Why?
| Molecular Sequence Data | 8 | 2015 | 2926 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 837 | 0.080 |
Why?
| Prognosis | 4 | 2021 | 3616 | 0.080 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 2009 | 160 | 0.080 |
Why?
| Genotype | 5 | 2015 | 1960 | 0.080 |
Why?
| Insulin Infusion Systems | 2 | 2004 | 316 | 0.080 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2018 | 1324 | 0.080 |
Why?
| Antigens | 3 | 2023 | 324 | 0.080 |
Why?
| Adrenocorticotropic Hormone | 2 | 2012 | 154 | 0.080 |
Why?
| Interleukin-17 | 1 | 2009 | 106 | 0.080 |
Why?
| Receptors, Chemokine | 2 | 2007 | 46 | 0.080 |
Why?
| Bacteria | 1 | 2015 | 767 | 0.080 |
Why?
| Amino Acid Sequence | 7 | 2015 | 2098 | 0.080 |
Why?
| Vitamin D Deficiency | 1 | 2010 | 167 | 0.080 |
Why?
| Immunodominant Epitopes | 2 | 2006 | 27 | 0.080 |
Why?
| Remission Induction | 2 | 2018 | 258 | 0.070 |
Why?
| Hydrocortisone | 2 | 2012 | 289 | 0.070 |
Why?
| Calcinosis | 1 | 2010 | 304 | 0.070 |
Why?
| Platelet Membrane Glycoprotein IIb | 1 | 2007 | 5 | 0.070 |
Why?
| Consensus | 2 | 2023 | 577 | 0.070 |
Why?
| Homicide | 1 | 1988 | 52 | 0.070 |
Why?
| Enzyme-Linked Immunospot Assay | 3 | 2011 | 34 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2009 | 3823 | 0.070 |
Why?
| Regression Analysis | 1 | 2010 | 1047 | 0.070 |
Why?
| Case-Control Studies | 5 | 2016 | 3326 | 0.070 |
Why?
| Safety | 1 | 2009 | 309 | 0.070 |
Why?
| Equipment Design | 1 | 2009 | 545 | 0.070 |
Why?
| Killer Cells, Natural | 2 | 2016 | 389 | 0.070 |
Why?
| Radioimmunoassay | 2 | 2017 | 170 | 0.070 |
Why?
| Rituximab | 3 | 2013 | 159 | 0.070 |
Why?
| CD40 Antigens | 1 | 2007 | 83 | 0.070 |
Why?
| Atherosclerosis | 1 | 2010 | 360 | 0.070 |
Why?
| Receptors, Interleukin-7 | 1 | 2006 | 26 | 0.070 |
Why?
| CD4 Lymphocyte Count | 3 | 2015 | 273 | 0.070 |
Why?
| Hybridomas | 2 | 2004 | 233 | 0.070 |
Why?
| Diabetic Retinopathy | 2 | 2005 | 162 | 0.070 |
Why?
| Mutation | 4 | 2015 | 3520 | 0.070 |
Why?
| Proteins | 2 | 2018 | 951 | 0.060 |
Why?
| Isoenzymes | 2 | 2004 | 311 | 0.060 |
Why?
| Mental Disorders | 1 | 2014 | 976 | 0.060 |
Why?
| Protein Tyrosine Phosphatases | 2 | 2004 | 149 | 0.060 |
Why?
| Signal Transduction | 3 | 2019 | 4809 | 0.060 |
Why?
| Disease Susceptibility | 2 | 2019 | 343 | 0.060 |
Why?
| Urban Population | 1 | 1988 | 433 | 0.060 |
Why?
| Acetamides | 1 | 2005 | 28 | 0.060 |
Why?
| Chemokines, CXC | 1 | 2005 | 64 | 0.060 |
Why?
| Risk | 3 | 2019 | 896 | 0.060 |
Why?
| Immunophenotyping | 2 | 2018 | 286 | 0.060 |
Why?
| Feces | 2 | 2018 | 402 | 0.060 |
Why?
| Blood Coagulation Factors | 1 | 1984 | 43 | 0.060 |
Why?
| Exanthema | 2 | 2019 | 80 | 0.060 |
Why?
| Coronary Artery Disease | 1 | 2010 | 721 | 0.060 |
Why?
| Niacinamide | 1 | 2004 | 71 | 0.060 |
Why?
| Immunoglobulin Fragments | 1 | 1983 | 15 | 0.060 |
Why?
| Tissue Donors | 1 | 2006 | 352 | 0.060 |
Why?
| Age Factors | 3 | 2017 | 3152 | 0.050 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 517 | 0.050 |
Why?
| Immunoassay | 1 | 2003 | 104 | 0.050 |
Why?
| Placebos | 2 | 2013 | 208 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 371 | 0.050 |
Why?
| Mice, Knockout | 1 | 2009 | 2736 | 0.050 |
Why?
| Cell Survival | 2 | 2019 | 1081 | 0.050 |
Why?
| Interleukin-4 | 2 | 2002 | 211 | 0.050 |
Why?
| Antigens, CD1 | 1 | 2002 | 59 | 0.050 |
Why?
| Cell Differentiation | 1 | 2009 | 1778 | 0.050 |
Why?
| Antibody Affinity | 2 | 2016 | 56 | 0.050 |
Why?
| Receptors, CXCR3 | 2 | 2016 | 16 | 0.050 |
Why?
| Siblings | 2 | 2018 | 252 | 0.050 |
Why?
| Gene Frequency | 2 | 2016 | 528 | 0.050 |
Why?
| Pyrimidines | 1 | 2005 | 391 | 0.050 |
Why?
| Canada | 2 | 2014 | 359 | 0.050 |
Why?
| Cell Proliferation | 2 | 2009 | 2333 | 0.050 |
Why?
| Preconception Care | 1 | 2002 | 33 | 0.050 |
Why?
| Labor, Obstetric | 1 | 2002 | 58 | 0.050 |
Why?
| Denmark | 2 | 2014 | 41 | 0.050 |
Why?
| Diseases in Twins | 2 | 2018 | 181 | 0.050 |
Why?
| Reference Values | 3 | 2009 | 818 | 0.050 |
Why?
| Pancreas | 2 | 2018 | 287 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2001 | 35 | 0.050 |
Why?
| Algorithms | 1 | 2008 | 1618 | 0.050 |
Why?
| Bacterial Proteins | 2 | 2018 | 777 | 0.050 |
Why?
| Pregnancy Outcome | 1 | 2003 | 368 | 0.050 |
Why?
| Vitamin D | 1 | 2004 | 362 | 0.050 |
Why?
| Administration, Topical | 1 | 2001 | 157 | 0.040 |
Why?
| Venoms | 1 | 2020 | 32 | 0.040 |
Why?
| Infant | 4 | 2022 | 8625 | 0.040 |
Why?
| Rats, Inbred BB | 2 | 1991 | 5 | 0.040 |
Why?
| Kinetics | 4 | 1994 | 1680 | 0.040 |
Why?
| Membrane Proteins | 2 | 2004 | 1089 | 0.040 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2020 | 14 | 0.040 |
Why?
| HLA-DR2 Antigen | 1 | 1999 | 8 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2019 | 83 | 0.040 |
Why?
| Antibodies, Heterophile | 1 | 1999 | 13 | 0.040 |
Why?
| Lymphocytes | 1 | 2002 | 356 | 0.040 |
Why?
| Hemorrhage | 1 | 1984 | 673 | 0.040 |
Why?
| Interleukin-7 | 1 | 2019 | 44 | 0.040 |
Why?
| ROC Curve | 1 | 2021 | 501 | 0.040 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2007 | 45 | 0.040 |
Why?
| Genes, MHC Class II | 1 | 1999 | 73 | 0.040 |
Why?
| HLA-A Antigens | 2 | 2011 | 50 | 0.040 |
Why?
| CD4-CD8 Ratio | 1 | 2019 | 20 | 0.040 |
Why?
| Prospective Studies | 4 | 2016 | 6818 | 0.040 |
Why?
| Mice, Inbred BALB C | 4 | 2011 | 1233 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 468 | 0.040 |
Why?
| Lymphopenia | 1 | 2019 | 50 | 0.040 |
Why?
| Databases, Factual | 1 | 2004 | 1298 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 289 | 0.040 |
Why?
| Macrophages | 2 | 1983 | 1333 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2023 | 745 | 0.040 |
Why?
| Leg | 1 | 2001 | 238 | 0.040 |
Why?
| Methylation | 1 | 2019 | 212 | 0.040 |
Why?
| Mucosal-Associated Invariant T Cells | 1 | 2018 | 16 | 0.040 |
Why?
| RNA, Viral | 2 | 1992 | 587 | 0.040 |
Why?
| Meals | 1 | 2020 | 105 | 0.040 |
Why?
| Seroconversion | 1 | 2018 | 47 | 0.040 |
Why?
| Insulin Lispro | 3 | 2004 | 35 | 0.040 |
Why?
| Wound Healing | 1 | 2001 | 298 | 0.040 |
Why?
| Therapies, Investigational | 1 | 2018 | 15 | 0.040 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2018 | 11 | 0.040 |
Why?
| B7-2 Antigen | 1 | 2017 | 26 | 0.040 |
Why?
| Seroepidemiologic Studies | 1 | 2018 | 154 | 0.040 |
Why?
| Ikaros Transcription Factor | 1 | 2018 | 18 | 0.040 |
Why?
| Glucose | 1 | 2023 | 995 | 0.040 |
Why?
| Single-Cell Analysis | 1 | 2019 | 200 | 0.040 |
Why?
| Cell Death | 1 | 2019 | 347 | 0.040 |
Why?
| Base Sequence | 4 | 1994 | 2207 | 0.040 |
Why?
| Risk Assessment | 2 | 2018 | 3274 | 0.040 |
Why?
| Aged | 6 | 2014 | 20859 | 0.040 |
Why?
| United States | 4 | 2015 | 13613 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2018 | 2061 | 0.040 |
Why?
| Antigens, CD | 2 | 2014 | 466 | 0.040 |
Why?
| Patient Care Planning | 1 | 2018 | 151 | 0.040 |
Why?
| Rats | 3 | 1991 | 5517 | 0.040 |
Why?
| Drug Discovery | 1 | 2018 | 129 | 0.040 |
Why?
| Structure-Activity Relationship | 2 | 2011 | 533 | 0.030 |
Why?
| Clone Cells | 3 | 2004 | 251 | 0.030 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.030 |
Why?
| Twins | 1 | 2018 | 247 | 0.030 |
Why?
| CD56 Antigen | 1 | 2016 | 35 | 0.030 |
Why?
| Genetic Markers | 1 | 1998 | 368 | 0.030 |
Why?
| Luminescent Measurements | 1 | 2017 | 74 | 0.030 |
Why?
| Leukocyte Common Antigens | 2 | 2007 | 79 | 0.030 |
Why?
| Receptors, IgG | 1 | 2016 | 68 | 0.030 |
Why?
| Environment | 1 | 2018 | 355 | 0.030 |
Why?
| Somalia | 1 | 2016 | 10 | 0.030 |
Why?
| Cell Count | 1 | 2017 | 321 | 0.030 |
Why?
| Antibody Specificity | 2 | 2007 | 191 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2012 | 1992 | 0.030 |
Why?
| Orphan Drug Production | 1 | 2015 | 6 | 0.030 |
Why?
| Cohort Studies | 3 | 2015 | 5348 | 0.030 |
Why?
| Organ Specificity | 2 | 2007 | 288 | 0.030 |
Why?
| Cities | 1 | 2016 | 97 | 0.030 |
Why?
| Forecasting | 1 | 1998 | 379 | 0.030 |
Why?
| Minnesota | 1 | 2016 | 144 | 0.030 |
Why?
| Intestines | 1 | 2018 | 337 | 0.030 |
Why?
| Immunity, Humoral | 1 | 2016 | 116 | 0.030 |
Why?
| Ethics, Medical | 1 | 2015 | 81 | 0.030 |
Why?
| HLA-DRB1 Chains | 2 | 2009 | 100 | 0.030 |
Why?
| Immunity, Innate | 2 | 2009 | 759 | 0.030 |
Why?
| Immunity, Active | 1 | 2014 | 10 | 0.030 |
Why?
| Proline | 1 | 1994 | 71 | 0.030 |
Why?
| Early Diagnosis | 1 | 2015 | 237 | 0.030 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 379 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2015 | 203 | 0.030 |
Why?
| Immunoglobulins | 1 | 2014 | 155 | 0.030 |
Why?
| Opportunistic Infections | 1 | 2014 | 48 | 0.030 |
Why?
| Single-Blind Method | 1 | 2014 | 286 | 0.030 |
Why?
| Drug Combinations | 1 | 2014 | 298 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 1994 | 341 | 0.030 |
Why?
| Cloning, Molecular | 1 | 2014 | 566 | 0.030 |
Why?
| Sequence Deletion | 1 | 1994 | 178 | 0.030 |
Why?
| Body Mass Index | 1 | 2021 | 2174 | 0.030 |
Why?
| Europe | 1 | 2014 | 369 | 0.030 |
Why?
| Mutagenesis | 1 | 1994 | 183 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 289 | 0.030 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2013 | 49 | 0.030 |
Why?
| Pregnancy | 2 | 2003 | 5922 | 0.030 |
Why?
| Transcription, Genetic | 3 | 1994 | 1376 | 0.030 |
Why?
| Escherichia coli Proteins | 1 | 1994 | 176 | 0.030 |
Why?
| Interleukin-10 | 1 | 2015 | 311 | 0.030 |
Why?
| Formamides | 1 | 1992 | 7 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2011 | 2135 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2015 | 524 | 0.030 |
Why?
| Herpesviridae | 1 | 2012 | 21 | 0.030 |
Why?
| Proteomics | 1 | 2018 | 903 | 0.030 |
Why?
| Immunocompromised Host | 1 | 2014 | 207 | 0.030 |
Why?
| Graft Survival | 1 | 2015 | 510 | 0.030 |
Why?
| Renin | 1 | 2012 | 36 | 0.030 |
Why?
| Postprandial Period | 1 | 2013 | 101 | 0.030 |
Why?
| Interleukins | 1 | 2014 | 243 | 0.030 |
Why?
| Lymph Nodes | 2 | 2006 | 467 | 0.030 |
Why?
| RNA, Antisense | 1 | 1992 | 20 | 0.030 |
Why?
| Virus Activation | 1 | 2012 | 81 | 0.030 |
Why?
| Herpesvirus 4, Human | 1 | 2012 | 129 | 0.020 |
Why?
| Gene Expression Regulation | 2 | 2014 | 2492 | 0.020 |
Why?
| Ligands | 2 | 2005 | 574 | 0.020 |
Why?
| HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| Prevalence | 2 | 2010 | 2488 | 0.020 |
Why?
| Societies, Medical | 1 | 2015 | 754 | 0.020 |
Why?
| Sample Size | 1 | 2011 | 138 | 0.020 |
Why?
| Phagocytosis | 2 | 1983 | 364 | 0.020 |
Why?
| Thallium Radioisotopes | 1 | 1991 | 7 | 0.020 |
Why?
| Receptors, Cell Surface | 2 | 1983 | 368 | 0.020 |
Why?
| Mass Screening | 1 | 2018 | 1119 | 0.020 |
Why?
| RNA Splicing | 1 | 1992 | 254 | 0.020 |
Why?
| Small Molecule Libraries | 1 | 2011 | 82 | 0.020 |
Why?
| Cognition Disorders | 1 | 2015 | 553 | 0.020 |
Why?
| Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.020 |
Why?
| HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| Isoantigens | 1 | 1990 | 20 | 0.020 |
Why?
| Polymerase Chain Reaction | 2 | 2009 | 1042 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 58 | 0.020 |
Why?
| Amino Acid Substitution | 2 | 2002 | 279 | 0.020 |
Why?
| Spleen | 3 | 2002 | 513 | 0.020 |
Why?
| Rats, Inbred Strains | 1 | 1990 | 414 | 0.020 |
Why?
| Linkage Disequilibrium | 1 | 2010 | 288 | 0.020 |
Why?
| HLA-DQ beta-Chains | 1 | 2009 | 62 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2016 | 2669 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2010 | 394 | 0.020 |
Why?
| Immunotherapy, Adoptive | 1 | 1991 | 194 | 0.020 |
Why?
| Microsatellite Repeats | 1 | 2009 | 144 | 0.020 |
Why?
| Chemokines | 1 | 2010 | 232 | 0.020 |
Why?
| Homozygote | 1 | 2009 | 195 | 0.020 |
Why?
| Pedigree | 1 | 2010 | 506 | 0.020 |
Why?
| Coculture Techniques | 1 | 2009 | 211 | 0.020 |
Why?
| Nausea | 1 | 2009 | 113 | 0.020 |
Why?
| Immunoblotting | 1 | 2009 | 313 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 1990 | 434 | 0.020 |
Why?
| Vomiting | 1 | 2009 | 132 | 0.020 |
Why?
| DNA Methylation | 1 | 2013 | 516 | 0.020 |
Why?
| Logistic Models | 1 | 2014 | 2040 | 0.020 |
Why?
| Immunoglobulin M | 1 | 2009 | 253 | 0.020 |
Why?
| Interferon-alpha | 1 | 2009 | 193 | 0.020 |
Why?
| Genetic Vectors | 1 | 2009 | 315 | 0.020 |
Why?
| Coronary Disease | 1 | 1991 | 399 | 0.020 |
Why?
| Exercise Test | 1 | 1991 | 585 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 1988 | 423 | 0.020 |
Why?
| DNA | 1 | 1994 | 1406 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 1994 | 1373 | 0.020 |
Why?
| Fever | 1 | 2009 | 294 | 0.020 |
Why?
| Cell Line | 2 | 2004 | 2806 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2009 | 194 | 0.020 |
Why?
| Up-Regulation | 1 | 2010 | 895 | 0.020 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 70 | 0.020 |
Why?
| Antisocial Personality Disorder | 1 | 1988 | 168 | 0.020 |
Why?
| Retrospective Studies | 3 | 2014 | 13708 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 384 | 0.020 |
Why?
| Models, Molecular | 1 | 2011 | 1450 | 0.020 |
Why?
| NF-kappa B | 1 | 2010 | 681 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 5102 | 0.020 |
Why?
| Chromogranins | 1 | 2006 | 14 | 0.020 |
Why?
| Psychotic Disorders | 1 | 1988 | 153 | 0.020 |
Why?
| Social Environment | 1 | 1988 | 309 | 0.020 |
Why?
| Phosphorylation | 1 | 2010 | 1694 | 0.020 |
Why?
| Hemodynamics | 1 | 1991 | 1093 | 0.020 |
Why?
| Glucagon | 1 | 2006 | 98 | 0.020 |
Why?
| Mice, Inbred C3H | 2 | 1983 | 259 | 0.020 |
Why?
| Keratins | 1 | 2006 | 176 | 0.020 |
Why?
| Thyroglobulin | 1 | 2005 | 18 | 0.020 |
Why?
| Chemokine CXCL11 | 1 | 2005 | 4 | 0.020 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 18 | 0.020 |
Why?
| Iodide Peroxidase | 1 | 2005 | 27 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 785 | 0.020 |
Why?
| Chemokine CXCL9 | 1 | 2005 | 22 | 0.020 |
Why?
| Alprostadil | 1 | 2005 | 38 | 0.020 |
Why?
| Chemokine CXCL10 | 1 | 2005 | 39 | 0.020 |
Why?
| Lupus Coagulation Inhibitor | 1 | 1984 | 6 | 0.020 |
Why?
| Fathers | 1 | 2005 | 49 | 0.020 |
Why?
| Interpersonal Relations | 1 | 1988 | 366 | 0.020 |
Why?
| Antigenic Variation | 1 | 2004 | 9 | 0.010 |
Why?
| Quality of Life | 1 | 2015 | 2580 | 0.010 |
Why?
| Dinoprostone | 1 | 2005 | 195 | 0.010 |
Why?
| Mice, Inbred CBA | 1 | 2004 | 63 | 0.010 |
Why?
| Infusion Pumps, Implantable | 1 | 2004 | 20 | 0.010 |
Why?
| Tetanus Toxin | 1 | 2003 | 5 | 0.010 |
Why?
| Postoperative Complications | 1 | 2015 | 2325 | 0.010 |
Why?
| Chaperonin 60 | 1 | 2003 | 14 | 0.010 |
Why?
| Insulin Aspart | 1 | 2004 | 26 | 0.010 |
Why?
| Injections, Subcutaneous | 1 | 2004 | 139 | 0.010 |
Why?
| Homeostasis | 1 | 2007 | 605 | 0.010 |
Why?
| Fibrosis | 1 | 2006 | 497 | 0.010 |
Why?
| Indicators and Reagents | 1 | 1983 | 107 | 0.010 |
Why?
| Biological Assay | 1 | 1983 | 123 | 0.010 |
Why?
| Fetal Macrosomia | 1 | 2003 | 60 | 0.010 |
Why?
| C-Reactive Protein | 1 | 2005 | 381 | 0.010 |
Why?
| Binding, Competitive | 1 | 1983 | 209 | 0.010 |
Why?
| Interleukin-2 | 1 | 2004 | 424 | 0.010 |
Why?
| Models, Biological | 1 | 1990 | 1753 | 0.010 |
Why?
| Antigens, CD1d | 1 | 2002 | 65 | 0.010 |
Why?
| Congenital Abnormalities | 1 | 2003 | 80 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2004 | 760 | 0.010 |
Why?
| Sex Factors | 1 | 1988 | 1901 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 79 | 0.010 |
Why?
| Insulin Resistance | 1 | 2010 | 1214 | 0.010 |
Why?
| Antigens, Surface | 1 | 2002 | 159 | 0.010 |
Why?
| Albuminuria | 1 | 2003 | 199 | 0.010 |
Why?
| Cell Division | 1 | 2004 | 796 | 0.010 |
Why?
| CTLA-4 Antigen | 1 | 2002 | 87 | 0.010 |
Why?
| Celiac Disease | 1 | 2005 | 270 | 0.010 |
Why?
| Diabetic Ketoacidosis | 1 | 2004 | 174 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2006 | 1743 | 0.010 |
Why?
| Major Histocompatibility Complex | 1 | 2002 | 223 | 0.010 |
Why?
| Alcoholism | 1 | 1988 | 819 | 0.010 |
Why?
| Multivariate Analysis | 1 | 2005 | 1561 | 0.010 |
Why?
| Gestational Age | 1 | 2003 | 797 | 0.010 |
Why?
| Birth Weight | 1 | 2003 | 477 | 0.010 |
Why?
| Alanine | 1 | 2000 | 104 | 0.010 |
Why?
| HLA-DQ alpha-Chains | 1 | 1999 | 17 | 0.010 |
Why?
| Glutamine | 1 | 2000 | 94 | 0.010 |
Why?
| Substance-Related Disorders | 1 | 1988 | 990 | 0.010 |
Why?
| Aging | 2 | 2007 | 1706 | 0.010 |
Why?
| Body Weight | 1 | 2004 | 960 | 0.010 |
Why?
| Mothers | 1 | 2005 | 740 | 0.010 |
Why?
| Incidence | 1 | 2005 | 2578 | 0.010 |
Why?
| Cell Line, Tumor | 1 | 2005 | 2913 | 0.010 |
Why?
| Survival Rate | 1 | 1999 | 1799 | 0.010 |
Why?
| Trifluoroethanol | 1 | 1994 | 1 | 0.010 |
Why?
| Polydeoxyribonucleotides | 1 | 1994 | 12 | 0.010 |
Why?
| Electrophoresis, Agar Gel | 1 | 1994 | 27 | 0.010 |
Why?
| Sodium Dodecyl Sulfate | 1 | 1994 | 22 | 0.010 |
Why?
| Colorado | 1 | 2005 | 4471 | 0.010 |
Why?
| Circular Dichroism | 1 | 1994 | 138 | 0.010 |
Why?
| DNA, Single-Stranded | 1 | 1994 | 114 | 0.010 |
Why?
| Genes, Viral | 1 | 1992 | 93 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 340 | 0.010 |
Why?
| Genome, Viral | 1 | 1992 | 124 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1991 | 136 | 0.010 |
Why?
| Computer Simulation | 1 | 1994 | 953 | 0.010 |
Why?
| Temperature | 1 | 1992 | 635 | 0.010 |
Why?
| Neoplasms | 1 | 1983 | 2340 | 0.000 |
Why?
| Lethal Dose 50 | 1 | 1983 | 12 | 0.000 |
Why?
| Fibrosarcoma | 1 | 1983 | 20 | 0.000 |
Why?
| Leukocytosis | 1 | 1983 | 36 | 0.000 |
Why?
| Neoplasm Transplantation | 1 | 1983 | 250 | 0.000 |
Why?
| Leukocyte Count | 1 | 1983 | 315 | 0.000 |
Why?
| Hypertension | 1 | 1991 | 1257 | 0.000 |
Why?
| Dogs | 1 | 1983 | 394 | 0.000 |
Why?
|
|
Gottlieb's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|